Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Published:2009-01 Issue:1 Volume:10 Page:25-34
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Cheng Ann-Lii,Kang Yoon-Koo,Chen Zhendong,Tsao Chao-Jung,Qin Shukui,Kim Jun Suk,Luo Rongcheng,Feng Jifeng,Ye Shenglong,Yang Tsai-Sheng,Xu Jianming,Sun Yan,Liang Houjie,Liu Jiwei,Wang Jiejun,Tak Won Young,Pan Hongming,Burock Karin,Zou Jessie,Voliotis Dimitris,Guan Zhongzhen

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis;El-Serag;Gastroenterology,2007

2. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001

3. International trends and patterns of primary liver cancer;McGlynn;Int J Cancer,2001

4. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa;Kirk;Hepatology,2004

5. Treatment modalities for hepatocellular carcinoma;Hung;Curr Cancer Drug Targets,2005

Cited by 5087 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer-associated fibroblasts promote the progression and chemoresistance of HCC by inducing IGF-1;Cellular Signalling;2024-12

2. STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma;Genes & Diseases;2024-11

3. Current research status of transarterial therapies for hepatocellular carcinoma;World Journal of Gastrointestinal Oncology;2024-09-15

4. Targeted Therapies for Hepatocellular Carcinoma Treatment;Liver Cancer - Multidisciplinary Approach;2024-09-11

5. A Bioequivalence Trial of Lenvatinib Mesylate Capsules in Healthy Subjects Under Fasting and Postprandial Conditions;Clinical Pharmacology in Drug Development;2024-09-10